^
Association details:
| Biomarker: | HRD |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | SSP-002358 (Proton pump inhibitor, Serotonin 4 receptor agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
6201 / 3 - Identification of SP-002, a highly selective USP1 inhibitor effectively inhibits HRD tumor growth and displays low hematotoxicity risk
Published date:
03/15/2023
Excerpt:
Oral administration of SP-002 led to completely tumor growth inhibition in MDA-MB-436 xenograft model, and combination of SP-002 and olaparib resulted in tumor regression. In conclusion, SP-002, a selective and potent USP1 inhibitor without significant hematotoxicity, that demonstrated excellent efficacy on treatment of HRD cancers.
